4-HO-DiPT

4-HO-DiPT
Clinical data
Other names	4-OH-DiPT; 4-Hydroxy-N,N-diisopropyltryptamine; Iprocin
Routes of; administration	Oral
Drug class	Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class A; US: Unscheduled;
Pharmacokinetic data
Onset of action	15–20 minutes; Luvesilocin: ≤1 hour
Elimination half-life	Luvesilocin (s.c.Tooltip subcutaneous injection): 2.7–4.1 h (as 4-HO-DiPT)
Duration of action	2–3 hours; Luvesilocin (s.c.): 3.6 hours (range ~3–4 hours)
Identifiers
	IUPAC name 3-[2-(diisopropylamino)ethyl]-1H-indol-4-ol;
CAS Number	132328-45-1 ; HCl: 63065-90-7 ;
PubChem CID	21854225;
ChemSpider	10579819 ;
UNII	YG9OUS518B; HCl: KE76PMQ2P3 ;
CompTox Dashboard (EPA)	DTXSID50618836 ;
ECHA InfoCard	100.214.853
Chemical and physical data
Formula	C16H24N2O
Molar mass	260.381 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N(CCc1c[nH]c2cccc(O)c12)C(C)C;
	InChI InChI=1S/C16H24N2O/c1-11(2)18(12(3)4)9-8-13-10-17-14-6-5-7-15(19)16(13)14/h5-7,10-12,17,19H,8-9H2,1-4H3 ; Key:KBRYKXCBGISXQV-UHFFFAOYSA-N ;
	(verify)

4-HO-DiPT, also known as 4-hydroxy-N,N-diisopropyltryptamine or as iprocin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It is taken orally. The drug has an unusually fast onset, short duration, and narrow dose range. Among orally administered psychedelics, it is one of the shortest-acting compounds known.

It acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT_2A receptor. Unlike many other psychedelic tryptamines, the drug appears to have far lower potency as an agonist of the serotonin 5-HT_2C receptor relative to the serotonin 5-HT_2A receptor. It is a derivative of DiPT, a higher homologue of psilocin (4-HO-DMT) and 4-HO-DET, and a skeletal isomer of 4-HO-DPT.

4-HO-DiPT was first described in the scientific literature by 1977. It was later described in greater detail by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). The drug was encountered as a novel designer drug by 2005. In the 2020s, a prodrug of 4-HO-DiPT known as luvesilocin (RE-104, FT-104; 4-GO-DiPT) was developed and is in clinical trials for the treatment of psychiatric disorders such as postpartum depression.